Research Summary

Dr. Maxwell Meng is a surgeon specializing in urologic cancers and laparoscopy. His interests in patient care include diagnosing and managing cancers of the genital and urinary organs, as well as minimally invasive treatments of both benign and malignant diseases. He is experienced in robotic surgery.

Meng is active in research to develop new treatment technologies.

Meng earned his medical degree at Johns Hopkins School of Medicine. He completed general surgery and urology training at UCSF, where he also completed fellowships in urologic oncology and minimally invasive surgery.

Education

A, 1991, Biochemical Sciences, Harvard College, Cambridge, MA
MD, 1995, Medicine, Johns Hopkins School of Medicine, Baltimore, MD
General surgery & urology, UCSF, 1995-2001
Laparoscopic fellowship, UCSF, 2001-2002
Oncology fellowship, UCSF, 2002-2003

Honors & Awards

  • 1987
    Westinghouse Science Talent Search, 7th Place
  • 1991
    Magna cum laude, Harvard College
  • 1995
    Alpha Omega Alpha, Johns Hopkins
  • 1999
    Third Prize, Northern California Urology Residents Seminar
  • 1999
    Pfizer Scholar in Urology
  • 2001
    Joseph F. McCarthy Essay Contest, 3rd Place, Western Section AUA
  • 2002
    Prostate Cancer Research Fellow
  • 2004
    William R. Smart Distinguished Teaching Award (selected by residents)
  • 2005
    Excellence in Direct Teaching, Academy of Medical Educators, UCSF
  • 2006
    Ambrose/Reed Socioeconomic Prize Essay (AUA)
  • 2006
    AUA leadership Program (1 of 16 selected nationally biennially)
  • 2006
    Miley B. Wesson Essay Contest, 2nd Place, AUA

Selected Publications

  1. Braun AE, Meng MV. Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma? J Natl Cancer Inst. 2024 Jul 01; 116(7):1002-1004.  View on PubMed
  2. Bell A, Rangaswami A, Murphy P, Meng M, Raphael R, Wu N, Goldsby R. Subsequent Renal Cancer Among Childhood Cancer Survivors: Analysis of Surveillance, Epidemiology, and End Results. J Pediatr Hematol Oncol. 2024 08 01; 46(6):e387-e392.  View on PubMed
  3. Lara PN, Tangen C, Heath EI, Gulati S, Stein MN, Meng M, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo R, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Lerner S, Thompson IM, Ryan CW. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024 Sep; 86(3):258-264.  View on PubMed
  4. Washington SL, Lonergan PE, Odisho AY, Meng MV, Porten SP. Association of household net worth with healthcare costs after radical cystectomy using real-world data. Cancer Med. 2024 Apr; 13(7):e7116.  View on PubMed
  5. Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. J Nucl Med. 2024 Feb 01; 65(2):199-205.  View on PubMed
  6. Wang EY, Armas-Phan M, Meng MV, Loeb S, Kenfield SA, Porten SP. Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life. Bladder Cancer. 2023; 9(4):323-326.  View on PubMed
  7. Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo RG, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Thompson IM, Lara PN. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2023 09 23; 402(10407):1043-1051.  View on PubMed
  8. Xie FH, Wu GH, Zhao X, Wan B, Yao R, Meng M, Liang L, Chen Q, Tang SJ. [Progress on health-related quality of life and its influencing factors in patients with tuberculosis sequelae]. Zhonghua Jie He He Hu Xi Za Zhi. 2023 Jun 12; 46(6):614-618.  View on PubMed
  9. Chappidi MR, Escobar D, Meng MV, Washington SL, Porten SP. Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols. Urol Oncol. 2023 08; 41(8):355.e19-355.e28.  View on PubMed
  10. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 10; 21(5):e394-e404.  View on PubMed
  11. Davis D, Seely D, Morash C, Armstrong J, Meng M, Lowe P, Kogan M. Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe. Altern Ther Health Med. 2023 May; 29(4):6-17.  View on PubMed
  12. Rancan C, Arias-Badia M, Dogra P, Chen B, Aran D, Yang H, Luong D, Ilano A, Li J, Chang H, Kwek SS, Zhang L, Lanier LL, Meng MV, Farber DL, Fong L. Exhausted intratumoral Vδ2- γδ T cells in human kidney cancer retain effector function. Nat Immunol. 2023 04; 24(4):612-624.  View on PubMed
  13. Li KD, Chu CE, Patel M, Meng MV, Morgan TM, Porten SP. Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Urol Oncol. 2023 07; 41(7):326.e1-326.e8.  View on PubMed
  14. Szymaniak JA, Washington SL, Cowan JE, Cooperberg MR, Lonergan PE, Nguyen HG, Meng MV, Carroll PR. The natural history of a delayed detectable PSA after radical prostatectomy. Prostate Cancer Prostatic Dis. 2023 Dec; 26(4):759-764.  View on PubMed
  15. Leow JJ, Tan WS, Tan WP, Tan TW, Chan VW, Tikkinen KAO, Kamat A, Sengupta S, Meng MV, Shariat S, Roupret M, Decaestecker K, Vasdev N, Chong YL, Enikeev D, Giannarini G, Ficarra V, Teoh JY, UroSoMe Collaborators. A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond. Front Surg. 2022; 9:879774.  View on PubMed
  16. Wallace A, Porten SP, Lo AA, Oreper D, Lounsbury N, Havnar C, Pechuan-Jorge X, Zill OA, Meng MV. Origins and Timing of Emerging Lesions in Advanced Renal Cell Carcinoma. Mol Cancer Res. 2022 06 03; 20(6):909-922.  View on PubMed
  17. Mujal AM, Combes AJ, Rao AA, Binnewies M, Samad B, Tsui J, Boissonnas A, Pollack JL, Argüello RJ, Meng MV, Porten SP, Ruhland MK, Barry KC, Chan V, Krummel MF. Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer. Cancer Immunol Res. 2022 04 01; 10(4):403-419.  View on PubMed
  18. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022 12; 5(6):714-718.  View on PubMed
  19. Chappidi MR, Yang H, Meng MV, Bivalacqua TJ, Daneshmand S, Holzbeierlein JM, Kaimakliotis HZ, Konety B, Liao JC, Pohar K, Steinberg GD, Taylor JM, Tyson MD, Willard B, Lotan Y, Porten SP, Kates M. Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. J Urol. 2022 Mar; 207(3):534-540.  View on PubMed
  20. Gore JL, Porten SP, Montgomery JS, Hamilton RJ, Meng MV, Sexton WJ, Psutka SP. Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic. Urol Oncol. 2023 02; 41(2):65-68.  View on PubMed

Go to UCSF Profiles, powered by CTSI